SCHEMBL30821925

SCHEMBL30821925

COC(=O)c1cc(Cl)cc(F)c1S(=O)(=O)Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.41
SERPINH1 P50454 1/20 0.40
POLB P06746 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
CASP3 P42574 1/20 0.40
KMT2A Q03164 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
EPAS1 Q99814 1/20 0.39
PDK2 Q15119 1/20 0.39
ACLY P53396 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
ALPL P05186 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SIRT6 Q8N6T7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19682390 1.00 ABL1 (0.41) ABL1SERPINH1POLBMCOLN3MEN1
SCHEMBL19682407 0.84 ABL1 (0.42) ABL1SERPINH1MEN1MAPTKMT2A
SCHEMBL30821680 0.82 MAOB (0.35) MEN1KMT2AACLYALDH1A1
SCHEMBL30298258 0.81 GAA (0.45) ABL1SERPINH1POLBMEN1KMT2A
SCHEMBL30821799 0.78 HPGD (0.38) MEN1MAPTKMT2AACLYALPL
SCHEMBL29689040 0.78 ABL1 (0.44) ABL1POLBMCOLN3MEN1MAPT
SCHEMBL15662614 0.77 ABL1 (0.45) ABL1SERPINH1POLBMEN1MAPT
SCHEMBL18765520 0.77 ABL1 (0.45) ABL1SERPINH1MEN1MAPTCASP3
SCHEMBL7034611 0.76 CA1 (0.45) POLBMCOLN3MAPTKMT2ASLC6A4
SCHEMBL19682400 0.76 ABL1 (0.44) ABL1SERPINH1MEN1MAPTCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085067-A1 CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF BOUNDLESS BIO INC (US) 2026-03-26 US disclosed
EP-4587437-A1 CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF Boundless Bio, Inc. (US) 2025-07-23 EP disclosed
WO-2024059563-A1 CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. (US) 2024-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085067-A1 CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF RRM1, RRM2B, RRM2 ABL1 3090/4885SERPINH1 2947/4885POLB 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.